SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-024717
Filing Date
2023-07-17
Accepted
2023-07-17 16:05:18
Documents
14
Period of Report
2023-07-11
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 4.01: Changes in Registrant's Certifying Accountant
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 52551
2 ex3-1.htm EX-3.1 136978
3 ex16-1.htm EX-16.1 3182
  Complete submission text file 0001493152-23-024717.txt   399838

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE evfm-20230711.xsd EX-101.SCH 3009
5 XBRL LABEL FILE evfm-20230711_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE evfm-20230711_pre.xml EX-101.PRE 22355
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3336
Mailing Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130
Business Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130 (858) 550-1900
Evofem Biosciences, Inc. (Filer) CIK: 0001618835 (see all company filings)

IRS No.: 208527075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36754 | Film No.: 231091680
SIC: 2834 Pharmaceutical Preparations